应用托伐普坦治疗糖尿病肾病综合征所致顽固性水肿个案分析

doi:10.3760/cma.j.issn.1007-1245.2024.07.023

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (7): 1172-1176.DOI: 10.3760/cma.j.issn.1007-1245.2024.07.023

应用托伐普坦治疗糖尿病肾病综合征所致顽固性水肿个案分析

刘睿茜杨阳高金祥

滨州医学院附属医院全科医学科，滨州　256613

收稿日期:2023-11-09 出版日期:2024-03-01 发布日期:2024-05-04
通讯作者: 高金祥，Email：13811717127@163.com

Tolvaptan for intractable edema in a patient with diabetic nephropathy syndrome

Liu Ruixi, Yang Yang, Gao Jinxiang

General Practice Department, Binzhou Medical University Hospital, Binzhou 256613, China

Received:2023-11-09 Online:2024-03-01 Published:2024-05-04
Contact: Gao Jinxiang, Email: 13811717127@163.com

摘要/Abstract

摘要：

糖尿病肾病综合征（diabetic nephropathy syndrome，DNS）是一种非免疫因素介导的继发性肾病综合征。由于其发病为非免疫因素介导，此类患者应用激素治疗无效，导致其引起的水肿在治疗上更加依赖利尿剂。新型利尿剂托伐普坦是一种选择性血管加压素V2受体拮抗剂，其发挥作用不依赖于白蛋白，目前主要用于减轻肝硬化、心力衰竭、抗利尿激素分泌异常综合征等导致的水肿，还可用于常染色体显性多囊肾病的辅助治疗，但在DNS患者中的应用较少。本文通过分享应用托伐普坦治疗1例顽固性水肿的DNS患者的经过，探讨托伐普坦治疗DNS患者的效果、安全性及未来前景。

关键词:

糖尿病肾病综合征, 托伐普坦, 水肿, 低蛋白血症

Abstract:

Diabetic nephropathy syndrome (DNS) is a secondary nephrotic syndrome mediated by nonimmune factors. Such patients become more dependent on diuretics for the treatment of their induced edema due to ineffectiveness of the hormone as the onset of their disease is nonimmune mediated. The novel diuretic tolvaptan, a selective vasopressin V2 receptor antagonist independent of albumin, is currently used primarily to reduce edema caused by cirrhosis, heart failure, and abnormal antidiuretic hormone secretion, and may also be used as an adjunctive therapy in autosomal dominant polycystic kidney disease, but is used less frequently in patients with DNS. In this article, we discuss the effectiveness, safety, and future prospects of tolvaptan in the treatment of patients with DNS by sharing the experience of a DNS patient with edema treated with tolvaptan.

Key words:

Diabetic nephropathy syndrome, Tolvaptan, Edema, Hypoalbuminemia

刘睿茜杨阳高金祥.

应用托伐普坦治疗糖尿病肾病综合征所致顽固性水肿个案分析 [J]. 国际医药卫生导报, 2024, 30(7): 1172-1176.

Liu Ruixi, Yang Yang, Gao Jinxiang.

Tolvaptan for intractable edema in a patient with diabetic nephropathy syndrome [J]. International Medicine and Health Guidance News, 2024, 30(7): 1172-1176.

参考文献

[1] Rondon-Berrios H. New insights into the pathophysiology of oedema in nephrotic syndrome [J]. Nefrologia, 2011, 31(2): 148-154. DOI: 10.3265/Nefrologia.pre2010.Nov.10724.
[2] 马千舒,马晓燕. 肾病综合征水肿之中医病机及西医发病机制浅析[J]. 云南中医中药杂志,2019,40(7):10-12. DOI:10.3969/j.issn.1007-2349.2019.07.004.
[3] Bhatt PR, McNeely EB, Lin TE, et al. Review of tolvaptan's pharmacokinetic and pharmacodynamic properties and drug interactions [J]. J Clin Med, 2014, 3(4):1276-1290. DOI: 10.3390/jcm3041276.
[4] Takagi K, Sato N, Ishihara S, et al. Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria [J]. Heart Vessels, 2018, 33(4): 413-420. DOI: 10.1007/s00380-017-1066-4.
[5] 柳继兴,宋霞,李桂英,等. 肾病综合征患者血浆AVP及尿液AQP2水平观察[J]. 解放军预防医学杂志,2009,27(3):223-223.
[6] 马骥,陈靖,顾勇,等.肾病综合征大鼠精氨酸血管加压素和V_2受体与水孔蛋白-2的研究及黄芪的治疗作用[J].肾脏病与透析肾移植杂志,1999(4):315-318. DOI: 10.3969/j.issn.1006-298X.1999.04.003
[7] Park ES, Huh YS, Kim GH. Is tolvaptan indicated for refractory oedema in nephrotic syndrome? [J]. Nephrology (Carlton), 2015, 20(2):103-106. DOI: 10.1111/nep.12348.
[8] Shimizu M, Ishikawa S, Yachi Y, et al. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome [J]. Pediatr Nephrol, 2014,29(5):915-917. DOI: 10.1007/s00467-013-2687-1.
[9] Tanaka A, Nakamura T, Sato E, et al. Different effects of tolvaptan in patients with idiopathic membranous nephropathy with nephrotic syndrome [J]. Intern Med, 2017, 56(2): 191-196. DOI: 10.2169/internalmedicine. 56.7539.
[10] Palmer ND, Freedman BI. Insights into the genetic architecture of diabetic nephropathy J]. Curr Diab Rep, 2012, 12(4): 423-431. DOI: 10.1007/s11892-012-0279-2.
[11] Iyengar SK, Abboud HE, Goddard KA, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND) [J]. Diabetes, 2007, 56(6): 1577-1585. DOI: 10.2337/db06-1154.
[12] Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy [J]. N Engl J Med, 1989, 320(18): 1161-1165. DOI: 10.1056/NEJM198905043201801.
[13] Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) [J]. Am J Kidney Dis, 2004, 44(5): 792-798.
[14] Helve J, Sund R, Arffman M, et al. Incidence of end-stage renal disease in patients with type 1 diabetes [J]. Diabetes Care, 2018, 41(3): 434-439. DOI: 10.2337/dc17-2364.
[15] Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men [J]. Am J Kidney Dis, 2005, 46(5): 871-880. DOI: 10.1053/j.ajkd.2005.08.015.
[16] 王荣. 肾病综合征患者如何合理使用利尿剂[J]. 肾脏病与透析肾移植杂志,2015(6):540-541.
[17] 王喆.«中国心力衰竭诊断和治疗指南2014»解读[J].中国临床医生杂志,2016,44(5):14-16. DOI:10.3969/j.issn.2095- 8552.2016.05.006
[18] Goldsmith SR, Bart BA, Burnett J. Decongestive therapy and renal function in acute heart failure: time for a new approach? [J]. Circ Heart Fail, 2014, 7(3): 531-535. DOI: 10.1161/CIRCHEARTFAILURE.113.000828.
[19] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [J]. Circulation, 2022, 145(18): e895-e1032. DOI: 10.1161/CIR.0000000000001063.
[20] Garbuzenko DV, Arefyev NO. Current approaches to the management of patients with cirrhotic ascites [J]. World J Gastroenterol, 2019, 25(28):3738-3752. DOI: 10.3748/wjg.v25.i28.3738.
[21] Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan [J]. J Am Soc Nephrol, 2018, 29(10): 2458-2470. DOI: 10.1681/ASN.2018060590.
[22] Sato E, Nakamura T, Amaha M, et al. Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure [J]. Int Heart J, 2014, 55(6): 533-538. DOI: 10.1536/ihj.14-190.

应用托伐普坦治疗糖尿病肾病综合征所致顽固性水肿个案分析

Tolvaptan for intractable edema in a patient with diabetic nephropathy syndrome

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

[1]	崔鹏翔杨凯华杨昕. 幼年型特发性关节炎儿童膝关节骨髓水肿的磁共振影像分析 [J]. 国际医药卫生导报, 2024, 30(2): 218-222.
[2]	罗育武郎德休周欣张淑娟叶倩如. 度普利尤单抗引起超敏反应1例报道并文献复习 [J]. 国际医药卫生导报, 2023, 29(5): 695-697.
[3]	申刚赵伟伟王梦君. 托伐普坦联合氢氯噻嗪在肾病综合征患者顽固性水肿中的应用效果 [J]. 国际医药卫生导报, 2023, 29(22): 3245-3249.
[4]	张纯冯娟娟柳洁陈敏方艳赵畅李雪芳廖靓俊. 颅内动脉瘤破裂伴蛛网膜下腔出血合并神经源性肺水肿患者的护理 [J]. 国际医药卫生导报, 2023, 29(19): 2816-2819.
[5]	牛欢丛晨阳. 房水炎性因子在糖尿病性黄斑水肿发病机制中的研究进展 [J]. 国际医药卫生导报, 2023, 29(17): 2369-2372.
[6]	陈丽丽朱成宝. 眼底激光联合IVR治疗RVO-ME患者的疗效观察 [J]. 国际医药卫生导报, 2023, 29(12): 1703-1707.
[7]	陈楚君, 陈玲, 施景华, 许婉珠, 罗泽槟. 乳腺癌患者术后患肢淋巴水肿延迟就医的质性研究 [J]. 国际医药卫生导报, 2022, 28(9): 1247-1250.
[8]	林友飞, 王姣焦, 吴迪, 刘毅萍, 陈晓红, 陈力舟. 新型冠状病毒肺炎患者血清白蛋白水平与患者病情的相关分析[J]. 国际医药卫生导报, 2022, 28(8): 1107-1111.
[9]	袁琛烨, 李玉群. 慢病自我管理模式应用于乳腺癌患者术后淋巴水肿中的效果评价[J]. 国际医药卫生导报, 2022, 28(8): 1126-1130.
[10]	袁琛烨, 周之音. 基于智慧医疗系统的管理模式预防乳腺癌患者术后淋巴水肿的效果观察 [J]. 国际医药卫生导报, 2022, 28(3): 336-340.
[11]	熊娜张金亮欧阳吁杨火秀赖华. 多学科协作诊疗模式下胎儿胸腔积液临床诊疗及转归[J]. 国际医药卫生导报, 2022, 28(19): 2714-2718.